Granules India is currently trading at Rs. 104.60, up by 3.10 points or 3.05% from its previous closing of Rs. 101.50 on the BSE.
The scrip opened at Rs. 103.00 and has touched a high and low of Rs. 106.00 and Rs. 102.50 respectively. So far 13703 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 120.00 on 22-Apr-2019 and a 52 week low of Rs. 79.00 on 10-Dec-2018.
Last one week high and low of the scrip stood at Rs. 106.00 and Rs. 93.00 respectively. The current market cap of the company is Rs. 2580.61 crore.
The promoters holding in the company stood at 42.90%, while Institutions and Non-Institutions held 17.69% and 39.41% respectively.
US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India for Fexofenadine Hydrochloride Tablets USP, 60 mg and 180 mg (OTC). It is bioequivalent to the reference listed drug product (RLD), Allegra Allergy Tablets, 60 mg and 180 mg, of Sanofi-Aventis US LLC.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).